IMIM: New evidence on molecular mechanisms involved in psoriasis outset

IMIM: New evidence on molecular mechanisms involved in psoriasis outset

News from IMIM

Two translational research studies by the University of Barcelona have described new immunologic mechanisms in psoriasis, a chronic cutaneous inflammatory disease which affects around the 2% of the population. The studies, published in the high impact scientific magazines Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology, have analysed the molecular processes involved in the IL-17 cytokine –a protein family of the immune system- with samples of patients with psoriasis. These results are important to understand the origins of psoriasis and develop more specific pharmaceutical treatments, since the IL-17 blocking is a new therapeutic strategy which is very effective when controlling this illness.

The studies have been led by Lluís Francesc Santamaria, Director of the group of Translationary Immunology of the University of Barcelona based at the Barcelona Science Park, together with researchers of the Hospital del Mar and the IMIM, among others.

More information:
IMIM Website

Reference articles:
E. Ruiz-Romeu, M. Ferran, A. Giménez-Arnau, B. Bugara, B. Lipert, J. Jura, E. Florencia, E. Prens, A. Celada, R. Pujol, L.F. Santamaria-Babí (2016). “MCPIP1 RNase is aberrantly distributed in psoriatic epidermis and rapidly induced by IL-17A”. Journal of Investigative Dermatology. May 2016. 

E. Ruiz-Romeu, M. Ferran, M. Sagristà, J. Gómez, A. Giménez-Arnau, K. Herszenyi, P. Hóllo, A. Celada, R. Pujol, L.F. Santamaria-Babí (2016). “Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis”. J Allergy Clin Immunol. April 2016.